BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact

Cord Blood Industry Consolidation Escalates in 2022

June 11, 2022 By Cade Hildreth (CEO) 2 Comments

cord blood industry

The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.

Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.

Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]

Filed Under: Cord Blood, HSCs Tagged With: cord blood, merger, news, trends

What Is An RMAT? List of Publicly Announced RMAT Designations (66)

June 11, 2022 By Cade Hildreth (CEO) 4 Comments

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

To date, 66 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced. However, the FDA states it has received 187 requests and issued 70, which means that a handful are not yet public knowledge.

Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.

Thus far, AlloVir is the only company to receive three RMATs, while six companies (Abeona Therapeutics, Allogene Therapeutics, Athersys, CARsgen Therapeutics, Rocket Pharmaceuticals, and CRISPR Therapeutics) have received two RMAT designations from the U.S. FDA.

[Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: RMAT

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

June 10, 2022 By Cade Hildreth (CEO) Leave a Comment

Umoja Bipharma and Treefrog Therapeutics
Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.

[Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cells

American Academy of Stem Cell Physicians To Hold Board Examination on June 18, 2022, at 2pm

June 7, 2022 By Cade Hildreth (CEO) Leave a Comment

AASCP Board Exam and Fellowship
American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications this June 18, 2022, in Miami!

MIAMI, June 6, 2022 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]

Filed Under: Press Releases, Stem Cell News

Stem Cell Treatments For Lungs? Paths to Relief and Recovery

June 3, 2022 By CadeHildreth 2 Comments

Stem Cell Treatments For Lungs

Lung diseases can be debilitating, making both medical leaders and patients interested in exploring stem cell treatments for lungs. Find out what you need to know about stem cell therapy for lungs, including risks, benefits, clinical trial progress and more. [Read more…]

Filed Under: Cell Therapy, Stem Cells

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 272
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.